Skip to main content

Table 2 Univariate and multivariate analysis of overall survival after the administration of docetaxel

From: Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer

Variables at docetaxel induction Univariate analysis Multivariate analysis
p value Hazard ratio 95.0 % CI p value Hazard ratio 95.0 % CI
Lower Upper Lower Upper
PSA (≥56.8 ng/mL vs <56.8) 0.115 1.991 0.845 4.693 0.894 0.929 0.317 2.729
Age(>73 vs ≤73) 0.623 0.810 0.349 1.879 0.944 0.964 0.343 2.704
Liver mets (yes vs no) 0.239 1.825 0.670 4.969 0.026 3.681 1.166 11.616
Local therapy (yes vs no) 0.137 0.218 0.029 1.624 0.206 0.213 0.019 2.339
Hb (<11.7 g/dL vs ≥11.7) 0.072 0.457 0.194 1.072 0.887 1.073 0.404 2.850
LDH (>225 IU/L vs ≤225) 0.045 2.385 1.019 5.578 0.078 2.500 0.903 6.915
Alb (<3.9 g/dL vs ≥3.9) 0.001 5.965 1.987 17.908 0.020 3.776 1.238 11.516
PSADT (≤1.4 months vs >1.4) 0.123 1.971 0.832 4.668 0.888 1.075 0.392 2.948
BSI (>1 % vs ≤1 %) 0.035 2.673 1.072 6.661 0.037 3.356 1.078 10.453
  1. PSA prostate-specific antigen, PSADT PSA doubling time, Hb hemoglobin, LDH lactate dehydrogenase, Alb albumin, BSI bone scan index, Liver mets liver metastasis
  2. The normal ranges of Hb, LDH and Alb were 11.3–14.5 g/dL, 116–199 IU/L and 4.2–5.4 g/dL, respectively